Industry News

Venaxis ®, Inc., announced that on September 21, 2016, the Company approved the grant of stock options to six new employees, hired in connection with the Company's acquisition of BiOptix Diagnostics, Inc., to purchase an aggregate of 95,000 shares of common stock. The stock options were granted as inducement grants material to the new employees entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635 (c)."/>
Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ Listing Rule 5635(c)(4)
Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it has entered into Exclusive Channel Collaborations with two startups backed by the Harvest Intrexon Enterprise Fund, sponsored by Harvest Capital Strategies, LLC. Through Intrexon's proprietary ActoBiotics™ Lactococcus lactis platform, these companies will pursue new..."/>
Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund
Ventripoint Diagnostics Ltd. announces an update on its strategy to develop, manufacture and distribute a family of Ventripoint's knowledge-based reconstruction products in the People's Republic of China. As previously announced in the Company's news release of November 3, 2015, the Company entered into an investment, distribution and management agreement pursuant to..."/>
Ventripoint Announces Establishment of a Joint Venture in China, Corporate Development Update, Private Placement and Issuance of Shares for Debt
Stemline Therapeutics, Inc. announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at 10:00 AM ET. The conference will be held at the Sofitel Hotel in New York, NY. A live webcast of the presentation can be viewed on the company’ s website at www.stemline.com.."/>
Stemline Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that the Company’ s management will participate in the Leerink Partners Rare Disease& Immuno-Oncology Roundtable in New York, NY. MacroGenics' presentation is scheduled to take place on..."/>
MacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that a review of the neurobiology and treatment efficacy of bremelanotide for hypoactive sexual desire disorder was presented at the International Society for Sexual Medicine 20 th World Meeting in Beijing,..."/>
Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
Agilent Technologies Inc. today announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow."/>
Agilent Technologies Launches New Panel for Fast FISH Testing
Immunovaccine Inc., a clinical-stage vaccine and immunotherapy company, today announced planned data presentations at upcoming scientific meetings in conjunction with collaborators at VIB, the Flemish life sciences research institute, and the Canadian Center for Vaccinology. These presentations will focus on DPX-RSV, Immunovaccine's lead infectious disease candidate in development for the prevention of respiratory syncytial virus."/>
Researchers to Present Data on Immunovaccine's Infectious Disease Pipeline at Three International Conferences
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that COO Jeffrey Davis, will be presenting for The Company at The Ladenburg Thalmann 2016 Healthcare Conference in New York City, September 27 th at 9:30 am ET. The following are the specific details regarding Abeona Therapeutics Presentation:."/>
Abeona Therapeutics to Present at Ladenburg Thalmann 2016 Healthcare Conference
PetVivo’ s Kush Continues to Demonstrate Effectiveness. MINNEAPOLIS, MN September 23, 2016 PetVivo Holdings, Inc. an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets continues to see positive results from Kush treatments to both dogs and horses. A particularly interesting case is a seven-year-old thoroughbred named Sarge Hudson."/>
PetVivo’s Kush Continues to Demonstrate Effectiveness
Shire plc will showcase data across its global leading immunoglobulin portfolio during the 17 th Biennial Meeting of the European Society for Immunodeficiencies, taking place September 21-24, 2016 in Barcelona. Presentations will include results of studies examining the safety, efficacy and tolerability profiles of Shire's IG treatment options for immune deficiencies, including primary immunodeficiency."/>
Shire to Showcase Continued Innovation and Leadership in Immune Deficiencies During European Society for Immunodeficiencies Biennial Meeting
Endo International plc today announced that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer, effective immediately."/>
Endo Names Paul Campanelli President and Chief Executive Officer
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the pricing of an underwritten offering of 2,500,000 shares of its common stock at a price of $4.00 per share. The gross proceeds to Catabasis from this offering are expected to be $10.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Catabasis has granted the underwriter a 30- day option to purchase up to an..."/>
Catabasis Pharmaceuticals Announces Pricing of $10 Million Offering of Common Stock
BioTime, Inc., a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference in New York City on Tuesday, September 27, 2016, at 1:00 p.m. Eastern Time/ 10:00 a.m. Pacific Time. The Ladenburg Thalmann Healthcare Conference is a well-respected event for investors who are specifically focused on healthcare and life sciences..."/>
BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
Endo International plc today announced that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer, effective immediately."/>
Endo Names Paul Campanelli President and Chief Executive Officer
Orexo AB disclosed on Thursday the issuance and repurchase 200,000 class C shares under its long-term incentive programme, LTIP 2016.. The company added that the entire issue of class C shares will thereafter be repurchased for SEK0.40 per share. According to the company, the share issue will enable the future delivery of ordinary shares to those participating in LTIP 2016, which was adopted by the annual general meeting on 15 April 2016.."/>
Orexo reports buyback of 200,000 Class C shares
Orexo AB disclosed on Thursday the issuance and repurchase 200,000 class C shares under its long-term incentive programme, LTIP 2016.. The company added that the entire issue of class C shares will thereafter be repurchased for SEK0.40 per share. According to the company, the share issue will enable the future delivery of ordinary shares to those participating in LTIP 2016, which was adopted by the annual general meeting on 15 April 2016.."/>
Orexo reports buyback of 200,000 Class C shares
Rockwell Medical stated on Thursday that it intends to market Calcitriol to hemodialysis patients in the US dialysis market following the stability data for completed finished product within specification. In conjunction with the stable encouraging data, the company expects Calcitriol to become commercially available in the US in approximately 45 days. Calcitriol has been shown to significantly reduce elevated parathyroid hormone levels."/>
Rockwell Medical plans commercial launch of Calcitriol in the US dialysis market
China Cord Blood Corporation, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2016 annual general meeting of shareholders at its Hong Kong office at 48/ F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 9, 2016. Shareholders of record as of October 28, 2016 will be..."/>
China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 9, 2016
Aradigm said on Thursday that it has completed the final dosing visit of the last patient in the ORBIT-3 and ORBIT-4 Phase 3 clinical studies of Pulmaquin for the treatment of patients with non-cystic fibrosis bronchiectasis who have chronic lung infections with Pseudomonas aeruginosa. The company stated that Pulmaquin is its proprietary inhaled ciprofloxacin, an investigational new medication being studied for the treatment of patients with..."/>
Aradigm doses last non-cystic fibrosis bronchiectasis patient under ORBIT-3 and ORBIT-4 Phase 3 studies of Pulmaquin
Alexion Pharmaceuticals, Inc. announced today that more than 1,500 employees around the world are volunteering in their respective communities as part of the Company’ s first Global Day of Service. For this inaugural event, Alexion employees are partnering with local non-profit organizations to participate in..."/>
Alexion Employees Volunteer Together in Company’s First Global Day of Service
DaVita Inc., a leading independent medical group and a leading provider of kidney care services in the United States, today announced that the 10 th annual Tour DaVita will kick off this weekend outside of Nashville, Tennessee. Over the course of three days, participants will bike between 180 and 230 miles through Middle Tennessee to increase awareness of kidney disease and vital health screenings while fundraising for Bridge of Life."/>
Over 500 Cyclists Ride in 10th Annual Tour DaVita to Raise Funds and Awareness for Kidney Disease
Orexo AB announced on Thursday the resolution to issue and immediately thereafter repurchase 200,000 class C shares. These shares are issued and repurchased in accordance with the long-term incentive programme, LTIP 2016, which was adopted by the annual general meeting on 15 April 2016.. According to the company, Danske Bank will subscribe for the entire issue of new class C shares at a subscription price of SEK0.40 per share, equal to the quota value of the shares."/>
Orexo resolves to issue and repurchase Class C shares

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology659 Articles
Consumer Discretionary626 Articles
Financials404 Articles
Industrials389 Articles
Health Care365 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.